BiotechTube
Orion Genomics

Orion Genomics

St. Louis, United States· Est.
oriongenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.8M

Overview

Orion Genomics is a private, established biotech firm with a dual focus on human health diagnostics and agricultural bioscience. The company's core strength lies in its epigenetic and genomic biomarker discovery platform, supported by over 100 patents and a CLIA-certified clinical laboratory for assay development. It commercializes its technology through partnerships, notably with the Malaysian Palm Oil Board via its subsidiary Orion Biosains for oil palm improvement, while also pursuing internal diagnostic pipelines. Orion appears to be in an early-revenue stage, generating income from services and partnerships rather than proprietary commercial products.

Genetics & GenomicsDiagnostics

Technology Platform

Proprietary genomics and epigenetics platform for biomarker discovery, utilizing sequencing technologies and a CLIA-certified lab for clinical assay development.

Funding History

2
Total raised:$17.8M
Series A$15M
Seed$2.8M

Opportunities

The global demand for precision agriculture and yield optimization presents a large market for its commercialized oil palm epigenetic screening service, with potential for expansion to other crops.
In human health, the growing liquid biopsy and early detection diagnostic market offers a significant opportunity if its epigenetic biomarker programs can be validated and commercialized.

Risk Factors

The company faces concentration risk from its reliance on the oil palm market and a key partnership in Malaysia.
In diagnostics, it competes in a crowded, capital-intensive field where commercial success depends on achieving clinical validation, regulatory approval, and market adoption against established players.

Competitive Landscape

In agriculture, Orion Biosains appears to have a first-mover advantage in epigenetic screening for oil palm, with technology born from a unique partnership. In human health diagnostics, it competes with numerous large-cap biotech (e.g., Illumina's Grail, Exact Sciences) and specialty diagnostic companies developing multi-omics and epigenetic cancer tests, requiring it to identify and defend niche biomarker advantages.

More companies in Diagnostics & Precision Medicine →More companies in United States →